KR102350102B1 - Composition for anti-inflammation comprising extract of fermented red ginseng with improved antioxidant activity as effective component - Google Patents
Composition for anti-inflammation comprising extract of fermented red ginseng with improved antioxidant activity as effective component Download PDFInfo
- Publication number
- KR102350102B1 KR102350102B1 KR1020190175949A KR20190175949A KR102350102B1 KR 102350102 B1 KR102350102 B1 KR 102350102B1 KR 1020190175949 A KR1020190175949 A KR 1020190175949A KR 20190175949 A KR20190175949 A KR 20190175949A KR 102350102 B1 KR102350102 B1 KR 102350102B1
- Authority
- KR
- South Korea
- Prior art keywords
- red ginseng
- fermented red
- extract
- composition
- fermented
- Prior art date
Links
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 94
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 15
- 239000000284 extract Substances 0.000 title abstract description 72
- 206010061218 Inflammation Diseases 0.000 title abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 64
- 208000027866 inflammatory disease Diseases 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 13
- 235000013376 functional food Nutrition 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 11
- 241000235646 Cyberlindnera jadinii Species 0.000 claims description 9
- 238000000855 fermentation Methods 0.000 claims description 9
- 230000004151 fermentation Effects 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 4
- 208000000491 Tendinopathy Diseases 0.000 claims description 4
- 206010043255 Tendonitis Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 201000004415 tendinitis Diseases 0.000 claims description 4
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 208000037976 chronic inflammation Diseases 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 2
- 206010033078 Otitis media Diseases 0.000 claims description 2
- 206010034016 Paronychia Diseases 0.000 claims description 2
- 241000029132 Paronychia Species 0.000 claims description 2
- 206010034038 Parotitis Diseases 0.000 claims description 2
- 201000007100 Pharyngitis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 201000005917 gastric ulcer Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 206010044008 tonsillitis Diseases 0.000 claims description 2
- 235000020710 ginseng extract Nutrition 0.000 claims 2
- 208000030090 Acute Disease Diseases 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 27
- 102000003820 Lipoxygenases Human genes 0.000 description 23
- 108090000128 Lipoxygenases Proteins 0.000 description 23
- 230000002401 inhibitory effect Effects 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 230000002292 Radical scavenging effect Effects 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 10
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 10
- 229930003935 flavonoid Natural products 0.000 description 10
- 150000002215 flavonoids Chemical class 0.000 description 10
- 235000017173 flavonoids Nutrition 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 241000208340 Araliaceae Species 0.000 description 6
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 6
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 description 6
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 235000008434 ginseng Nutrition 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 244000063299 Bacillus subtilis Species 0.000 description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 description 5
- 244000199866 Lactobacillus casei Species 0.000 description 5
- 235000013958 Lactobacillus casei Nutrition 0.000 description 5
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 5
- 229940017800 lactobacillus casei Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- -1 pH adjusters Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 241001116389 Aloe Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006388 chemical passivation reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- A23Y2220/00—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 항산화 활성이 증진된 발효 홍삼 추출물을 유효성분으로 함유하는 항염증용 조성물에 관한 것으로, 본 발명의 발효 홍삼 추출물은 천연 유래의 물질로 인체에 안전하고 장기간 사용하여도 부작용이 없으며 항염 효과가 우수하므로, 염증 개선을 위한 식품 및 치료제로 유용하게 사용할 수 있다. The present invention relates to an anti-inflammatory composition comprising a fermented red ginseng extract with enhanced antioxidant activity as an active ingredient. Since it is excellent, it can be usefully used as a food and therapeutic agent for improving inflammation.
Description
본 발명은 항산화 활성이 증진된 발효 홍삼 추출물을 유효성분으로 함유하는 항염증용 조성물에 관한 것이다.The present invention relates to an anti-inflammatory composition comprising a fermented red ginseng extract with enhanced antioxidant activity as an active ingredient.
염증반응은 조직(세포)의 손상이나 외부감염원(박테리아, 곰팡이, 바이러스, 다양한 종류의 알레르기 유발물질)에 감염되었을 때 국소 혈관과 체액 중 각종 염증 매개인자 및 면역세포가 관련되어 효소 활성화, 염증매개 물질 분비, 체액 침윤, 세포 이동, 조직 파괴 등 일련의 복합적인 생리적 반응과 홍반, 부종, 발열, 통증 등 외적 증상이 나타나는 것을 의미한다. 정상인 경우 염증반응은 외부감염원을 제거하고 손상된 조직을 재생하여 생명체 기능회복작용을 하지만, 항원이 제거되지 않거나 내부 물질이 원인이 되어 염증반응이 과도하거나 지속적으로 일어나면 오히려 질환의 주요 병리현상(과민성질환, 만성 염증)이 되며, 수혈, 약물투여, 장기이식 등 치료과정에서도 장해요인이 된다.Inflammation reaction occurs when tissues (cells) are damaged or infected with external infectious agents (bacteria, fungi, viruses, and various types of allergens). It refers to the appearance of a series of complex physiological reactions such as substance secretion, body fluid infiltration, cell migration, and tissue destruction and external symptoms such as erythema, edema, fever, and pain. In normal cases, the inflammatory reaction removes the external infectious agent and regenerates the damaged tissue to restore the function of the living organism. , chronic inflammation) and become an obstacle in the treatment process such as blood transfusion, drug administration, and organ transplantation.
현재까지는 염증 반응의 물리적 불편함을 감소시키는 제약학적 제제를 투여하여 치료하고 있으나 일반적인 항염증성 약제는 광범위한 질병의 치료에 사용되고, 동일한 약제가 종종 상이한 질병의 치료에 이용되는 경우가 있기 때문에 치료작용 및 부작용을 공유하게 된다. 따라서 부작용 때문에 장기적으로 사용하기가 곤란하며, 결과적으로 현재까지의 치료법에 부작용의 심각성이 너무 크기 때문에 새롭거나 개선된 염증 질환 치료제 개발은 필수적이고 시급한 실정이며, 부작용에 대한 우려가 없는 인체에 안전한 항염제의 필요성이 대두되고 있다.Until now, treatment has been done by administering pharmaceutical agents that reduce the physical discomfort of the inflammatory response, but general anti-inflammatory drugs are used for the treatment of a wide range of diseases, and the same drug is often used for the treatment of different diseases. side effects are shared. Therefore, it is difficult to use long-term due to side effects, and as a result, since the severity of side effects is too great for the current treatment, the development of a new or improved inflammatory disease treatment is essential and urgent. The need for is emerging.
홍삼(red ginseng)은 생인삼(수삼)을 수증기 또는 기타 방법으로 쪄서 익혀 건조한 것으로, 수삼을 찐 후 건조과정에서 갈색화 반응, 즉 갈변 반응이 일어나 담황갈색이나 적갈색을 띄게 된다. 인삼의 여러 종류 중에서도 홍삼이 백삼보다 우수한 효능을 나타내는 부분이 알려져 있다. 예를 들면, 노화억제와 관련된 지질과 산화 억제 및 항산화 활성, 알코올 해독 관련 효소 활성에 미치는 효과 등에서 홍삼은 백삼보다 뛰어난 효능을 나타내는 것으로 보고되고 있다.Red ginseng is fresh ginseng (fresh ginseng) steamed and dried by steaming or other methods. Among various types of ginseng, it is known that red ginseng exhibits superior efficacy than white ginseng. For example, it has been reported that red ginseng exhibits superior efficacy than white ginseng in the effects of lipids related to aging inhibition, oxidation inhibition, antioxidant activity, and enzyme activity related to alcohol detoxification.
발효는 오랜 역사를 가진 생물학 기술로, 유산균, 곰팡이, 효모 등의 인체에 유익한 미생물의 효소작용을 이용하여 식품 내 천연 고분자 물질을 저분자 물질로 변화시켜 체내 흡수율을 높이고, 다당체, 올리고당, 사포닌, 펩타이드, 피틴산 등의 새로운 발효산물을 얻거나 또는 상호 간의 시너지 작용에 의해 생리활성 및 기능성 효능이 상승되는 것으로 알려져 왔다. 탄수화물과 단백질을 주로 분해하는 미생물 중 하나인 곰팡이 균주는 증식하면서 분비하는 효소에 의해 생성되는 당류, 아미노산류, 유기산류 등의 맛 성분이 품질을 결정하며, 폴리페놀류 등의 유효성분이 증가함으로써 다양한 생리활성 작용을 나타낸다. Fermentation is a biological technology with a long history. It uses the enzyme action of microorganisms beneficial to the human body such as lactic acid bacteria, mold, yeast, etc. It has been known that physiological activity and functional efficacy are increased by obtaining new fermentation products such as , phytic acid, or synergistic action between them. In mold strains, one of the microorganisms that mainly decompose carbohydrates and proteins, taste components such as sugars, amino acids, and organic acids produced by enzymes secreted while proliferating determine the quality, and active ingredients such as polyphenols increase shows active action.
한편, 한국공개특허 제2012-0129474호에는 '홍삼 추출물을 유효성분으로 함유하는 알레르기성 염증질환 치료 및 예방용 조성물'이 개시되어 있고, 한국등록특허 제1751398호에는 '당귀, 산수유, 녹용, 홍삼, 숙지황, 침향 및 벌꿀을 포함하는 항염증 조성물'이 개시되어 있으나, 본 발명의 항산화 활성이 증진된 발효 홍삼 추출물을 유효성분으로 함유하는 항염증용 조성물에 대해서는 기재된 바가 없다.On the other hand, Korea Patent Publication No. 2012-0129474 discloses 'a composition for treating and preventing allergic inflammatory disease containing red ginseng extract as an active ingredient', and Korean Patent No. 1751398 discloses 'Angi Gui, Cornus oil, deer antler, and red ginseng'. , 'Anti-inflammatory composition comprising Sukhumvitae, aloes and honey' is disclosed, but there is no description of an anti-inflammatory composition containing the fermented red ginseng extract with enhanced antioxidant activity of the present invention as an active ingredient.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명자들은 홍삼 분말에 캔디다 유틸리스(Candida utilis)를 접종하여 3일간 발효시킨 후 물로 추출하여 발효 홍삼 물 추출물을 제조하였고, 제조된 발효 홍삼 물 추출물이 발효되지 않은 홍삼 물 추출물에 비해 총 페놀 및 플라보노이드 함량이 증가되고 DPPH 라디칼 소거 활성이 우수할 뿐만 아니라, 발효되지 않은 홍삼 물 추출물 및 발효 홍삼 에탄올 추출물에 비해 항염증 효과가 현저하게 증가되는 것을 확인함으로써, 본 발명을 완성하였다.The present invention was derived from the above requirements, and the present inventors inoculated Candida utilis into red ginseng powder, fermented for 3 days, and extracted with water to prepare a fermented red ginseng water extract, and prepared fermented red ginseng water Compared to the unfermented red ginseng water extract, the total phenol and flavonoid content was increased and the DPPH radical scavenging activity was excellent, and the anti-inflammatory effect was significantly increased compared to the unfermented red ginseng water extract and the fermented red ginseng ethanol extract. By confirming, the present invention was completed.
상기 과제를 해결하기 위해 본 발명은 항산화 활성이 증진된 발효 홍삼 추출물을 유효성분으로 포함하는 염증성 질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In order to solve the above problems, the present invention provides a health functional food composition for the prevention or improvement of inflammatory diseases comprising a fermented red ginseng extract with enhanced antioxidant activity as an active ingredient.
또한, 본 발명은 항산화 활성이 증진된 발효 홍삼 추출물을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases comprising a fermented red ginseng extract with enhanced antioxidant activity as an active ingredient.
본 발명의 발효 홍삼 추출물은 천연 유래의 물질로 인체에 안전하고 장기간 사용하여도 부작용이 없으며 항염 효과가 우수하므로, 염증 개선을 위한 식품 및 치료제로 유용하게 사용할 수 있다. The fermented red ginseng extract of the present invention is a natural substance, safe to the human body, has no side effects even after long-term use, and has excellent anti-inflammatory effect, so it can be usefully used as a food and therapeutic agent for improving inflammation.
도 1은 비발효 홍삼 물 추출물(NF) 및 발효 홍삼 물 추출물(F/3) 내의 총 페놀 함량을 측정한 결과이다.
도 2는 비발효 홍삼 물 추출물(NF) 및 발효 홍삼 물 추출물(F/3) 내의 플라보노이드 함량을 측정한 결과이다.
도 3은 비발효 홍삼 물 추출물(NF) 및 발효 홍삼 물 추출물(F/3)의 DPPH 라디칼 소거 활성(DPPH radical scavenging activity)을 측정한 결과이다. 양성대조군은 BHT(butylated hydroxytoluene, 0.05%)를 처리한 것이다.
도 4는 비발효 홍삼 물 추출물(NF)과 홍삼 물 추출물(F/3-W) 및 발효 홍삼 에탄올 추출물(F/3-E)의 리폭시게나아제 저해 활성(lipoxygenase inhibition activity)을 측정하여 비교한 결과이다. 양성대조군은 IDM(Indomethacine, 0.05%)을 처리한 것이다.
도 5는 발효 균주에 따른 발효 홍삼 물 추출물의 리폭시게나아제 저해 활성을 측정한 결과이다. 양성대조군은 IDM(Indomethacine, 0.05%)을 처리한 것이고, NF는 비발효 홍삼 물 추출물 처리군이며, Lc는 락토바실러스 카제이(Lactobacillus casei); Bs는 바실러스 서틸리스(Bacillus subtilis); 및 Cu는 캔디다 유틸리스(Candida utilis)를 각각 접종하여 제조한 발효 홍삼 물 추출물 처리군을 나타낸다.
도 6은 발효 균주로 캔디다 유틸리스를 접종한 후 발효 기간에 따른 발효 홍삼 물 추출물의 리폭시게나아제 저해 활성을 측정한 결과이다. 양성대조군은 IDM(Indomethacine, 0.05%)을 처리한 것이고, NF는 비발효 홍삼 물 추출물 처리군; F/1은 1일간; F/2는 2일간; F/3은 3일간; F/4는 4일간; 및 F/5는 5일간 각각 발효시켜 제조한 발효 홍삼 물 추출물 처리군을 나타낸다.1 is a result of measuring the total phenol content in non-fermented red ginseng water extract (NF) and fermented red ginseng water extract (F/3).
2 is a result of measuring the content of flavonoids in non-fermented red ginseng water extract (NF) and fermented red ginseng water extract (F/3).
Figure 3 is a result of measuring the DPPH radical scavenging activity (DPPH radical scavenging activity) of non-fermented red ginseng water extract (NF) and fermented red ginseng water extract (F/3). The positive control group was treated with BHT (butylated hydroxytoluene, 0.05%).
4 is a comparison of the lipoxygenase inhibition activity of non-fermented red ginseng water extract (NF), red ginseng water extract (F/3-W), and fermented red ginseng ethanol extract (F/3-E). is the result The positive control group was treated with IDM (Indomethacine, 0.05%).
5 is a result of measuring the lipoxygenase inhibitory activity of the fermented red ginseng water extract according to the fermented strain. The positive control group was treated with IDM (Indomethacine, 0.05%), NF was the non-fermented red ginseng water extract treated group, Lc was Lactobacillus casei ( Lactobacillus casei ); Bs is Bacillus subtilis ( Bacillus subtilis ); and Cu denotes a fermented red ginseng water extract treatment group prepared by inoculating each Candida utilis.
6 is a result of measuring the lipoxygenase inhibitory activity of the fermented red ginseng water extract according to the fermentation period after inoculation of Candida utilis as a fermented strain. The positive control group was treated with IDM (Indomethacine, 0.05%), and NF was the group treated with non-fermented red ginseng water extract; F/1 is 1 day; F/2 for 2 days; F/3 is 3 days; F/4 is 4 days; and F/5 represents the fermented red ginseng water extract treatment group prepared by fermenting each for 5 days.
본 발명의 목적을 달성하기 위하여, 본 발명은 항산화 활성이 증진된 발효 홍삼 추출물을 유효성분으로 포함하는 염증성 질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In order to achieve the object of the present invention, the present invention provides a health functional food composition for preventing or improving inflammatory diseases comprising a fermented red ginseng extract with enhanced antioxidant activity as an active ingredient.
본 발명의 일 구현 예에 따른 염증성 질환의 예방 또는 개선용 건강기능식품 조성물에서, 상기 발효 홍삼은 홍삼 분말에 곰팡이균을 접종하여 발효한 것일 수 있고, 바람직하게는 홍삼 분말에 캔디다 유틸리스(Candida utilis)를 접종하고 2~5일 동안 발효한 것일 수 있으며, 더욱 바람직하게는 2.5~3.5일 동안 발효한 것일 수 있으며, 가장 바람직하게는 3일 동안 발효한 것일 수 있으나, 이에 제한되지 않는다.In the present invention, one functional food for the prevention or amelioration of inflammatory diseases in accordance with an embodiment the composition of the fermented ginseng may be one by inoculating the fungus in the red ginseng powder fermented, preferably Candida utility less (Candida in red ginseng powder utilis ) may be inoculated and fermented for 2 to 5 days, more preferably may be fermented for 2.5 to 3.5 days, and most preferably may be fermented for 3 days, but is not limited thereto.
상기 발효 홍삼 추출물은 물, 탄소수 1 내지 4의 저급 알코올 또는 이들의 혼합물을 추출용매로 이용하여 추출한 것일 수 있고, 바람직하게는 물을 추출용매로 이용하여 추출한 것일 수 있으나, 이에 제한되지 않는다.The fermented red ginseng extract may be extracted using water, a lower alcohol having 1 to 4 carbon atoms, or a mixture thereof as an extraction solvent, and preferably may be extracted using water as an extraction solvent, but is not limited thereto.
본 발명의 상기 건강기능식품 조성물은, 비발효 홍삼 물 추출물에 비해 총 페놀 및 플라보노이드의 함량이 높고 DPPH 라디칼 소거 활성이 우수하며, 비발효 홍삼 물 추출물 및 발효 홍삼 에탄올 추출물에 비해 염증유발 인자인 리폭시게나아제(lipoxygenase) 생성 억제 활성이 증가된 발효 홍삼 물 추출물을 유효성분으로 포함하고 있어, 염증성 질환에 효과가 있다.The health functional food composition of the present invention has a higher content of total phenol and flavonoids than the water extract of unfermented red ginseng, and has excellent DPPH radical scavenging activity, and lipok, an inflammation-inducing factor, compared to the water extract of unfermented red ginseng and ethanol extract of fermented red ginseng. As it contains fermented red ginseng water extract with increased lipoxygenase production inhibitory activity as an active ingredient, it is effective in inflammatory diseases.
상기 염증성 질환의 예방 또는 개선용 건강기능식품 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽, 발포정 및 음료 중에서 선택된 어느 하나의 제형으로 제조될 수 있으나, 이에 제한되지 않는다. 상기 건강기능식품 조성물은 염증성 질환의 예방 또는 개선하기 위해 섭취할 수 있는 것이면 특별히 제한되지 않는다.The health functional food composition for preventing or improving the inflammatory disease may be prepared in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup, effervescent tablet and beverage, but is not limited thereto. The health functional food composition is not particularly limited as long as it can be ingested to prevent or improve inflammatory diseases.
본 발명의 발효 홍삼 추출물을 식품첨가물로 사용하는 경우, 상기 발효 홍삼 추출물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 발효 홍삼 추출물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양의로 첨가된다. 그러나 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 안전성 면에서 아무런 문제가 없는 범위의 양으로 사용될 수 있다.When the fermented red ginseng extract of the present invention is used as a food additive, the fermented red ginseng extract may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method. The active ingredient may be used appropriately depending on the purpose of its use (prevention or improvement). In general, in the production of food or beverage, the fermented red ginseng extract of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material. However, in the case of long-term intake for the purpose of health control, it can be used in an amount within a range that does not cause any problems in terms of safety.
상기 식품의 종류에는 특별한 제한은 없다. 상기 건강기능식품 조성물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다. 상기 음료는 탄산음료, 기능성이온음료, 쥬스(예를 들어, 사과, 배,포도, 알로에, 감귤, 복숭아, 당근, 토마토쥬스 등), 식혜 등을 포함한다. There is no particular limitation on the type of the food. Examples of foods to which the health functional food composition can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea There are drinks, alcoholic beverages, vitamin complexes, etc., and includes all health foods in the ordinary sense. The beverage includes carbonated beverages, functional ionic beverages, juices (eg, apple, pear, grape, aloe, tangerine, peach, carrot, tomato juice, etc.), sikhye, and the like.
본 발명의 기능성 식품은 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함시킬 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등), 디사카라이드(예컨대, 말토스, 수크로오스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등) 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다. 상기 건강기능식품 조성물 외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다. The functional food of the present invention includes ingredients commonly added during food production, for example, proteins, carbohydrates, fats, nutrients and seasonings. For example, when manufactured as a drink, natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredient. The natural carbohydrates include monosaccharides (eg, glucose, fructose, etc.), disaccharides (eg, maltose, sucrose, etc.), oligosaccharides, polysaccharides (eg, dextrin, cyclodextrin, etc.) or sugar alcohols (eg, , xylitol, sorbitol, erythritol, etc.) is preferable. As the flavoring agent, natural flavoring agents (eg, taumatine, stevia extract, etc.) and synthetic flavoring agents (eg, saccharin, aspartame, etc.) may be used. In addition to the above health functional food composition, various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonic acid It may further contain a carbonation agent and the like used in beverages.
상기 건강기능식품 조성물 이외에 여러 가지 영양제, 비타민, 저해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다. 이러한 상기 첨가되는 성분의 비율은 크게 중요하진 않지만 본 발명의 건강기능식품 조성물 100 중량부에 대하여, 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the health functional food composition, various nutrients, vitamins, inhibitors, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, It may further contain a carbonation agent, etc. used in carbonated beverages. The ratio of these added ingredients is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.
또한, 본 발명은 발효 홍삼 추출물을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases comprising a fermented red ginseng extract as an active ingredient.
상기 발효 홍삼 추출물은 바람직하게는 발효 홍삼 물 추출물일 수 있다.The fermented red ginseng extract may preferably be a fermented red ginseng water extract.
본 발명의 염증성 질환의 예방 또는 치료용 약학조성물에서, 상기 염증성 질환은 알레르기, 피부염, 아토피, 결막염, 치주염, 비염, 중이염, 인후염, 편도염, 폐렴, 위궤양, 위염, 크론병, 대장염, 통풍, 강직성 척추염, 류마티스 열, 루푸스, 섬유근통(fibromyalgia), 건선관절염, 골관절염, 류마티스 관절염, 견관절주위염, 건염, 건초염, 건주위염, 근육염, 간염, 방광염, 신장염, 쇼그렌 증후군(sjogren's syndrome), 다발성 경화증, 및 급성 및 만성 염증 질환으로 이루어지는 군으로부터 선택되는 어느 하나일 수 있으나, 이에 제한되지 않는다.In the pharmaceutical composition for preventing or treating inflammatory diseases of the present invention, the inflammatory diseases are allergy, dermatitis, atopic dermatitis, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, gout, ankylosing Spondylitis, rheumatic fever, lupus, fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, parotiditis, tendinitis, tendinitis, paronychia, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis, and acute And it may be any one selected from the group consisting of chronic inflammatory diseases, but is not limited thereto.
본 발명의 상기 약학 조성물은, 염증유발 인자인 리폭시게나아제(lipoxygenase)의 저해 활성이 증가된 발효 홍삼 물 추출물을 유효성분으로 포함하고 있어, 염증성 질환에 효과가 있다. 또한, 본 발명에 따른 상기 발효 홍삼 물 추출물은 항산화 효과가 우수하다.The pharmaceutical composition of the present invention contains, as an active ingredient, a water extract of fermented red ginseng with increased inhibitory activity of lipoxygenase, an inflammation-inducing factor, and is effective in inflammatory diseases. In addition, the fermented red ginseng water extract according to the present invention has excellent antioxidant effect.
본 발명의 상기 발효 홍삼 추출물을 포함하는 약학 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 또는 희석제를 더 포함할 수 있다. The pharmaceutical composition comprising the fermented red ginseng extract of the present invention may further include an appropriate carrier, excipient or diluent commonly used in the preparation of the pharmaceutical composition.
본 발명의 약학 조성물의 약학적 투여 형태는 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 조합으로 사용될 수 있다.The pharmaceutical dosage form of the pharmaceutical composition of the present invention may be used alone or in combination with other pharmaceutically active compounds, as well as suitable combinations.
본 발명에 따른 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제제, 외용제, 좌제 및 주사제의 형태로 제형화하여 사용될 수 있다. 상기 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함한 다양한 화합물 혹은 혼합물을 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 상기 발효물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트, 수크로오스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이 외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔, 마크로골, 트윈 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The pharmaceutical composition according to the present invention may be formulated in the form of oral preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, external preparations, suppositories, and injections, respectively, according to conventional methods. . Carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, and the like. In the case of formulation, it is prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc. in the fermented product. prepared by mixing In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid formulations for oral use include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As the base of the suppository, Witepsol, macrogol, Tween 61, cacao butter, laurin fat, glycerogelatin, and the like can be used.
본 발명의 상기 약학 조성물의 바람직한 투여량은 환자의 상태 및 체중,질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 본 발명의 약학 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내(intracerebroventricular) 주사에 의해 투여될 수 있다.The preferred dosage of the pharmaceutical composition of the present invention varies depending on the patient's condition and body weight, the degree of disease, drug form, administration route and period, but may be appropriately selected by those skilled in the art. The pharmaceutical composition of the present invention may be administered to mammals such as rats, mice, livestock, and humans by various routes. Any mode of administration can be envisaged, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
이하, 본 발명을 실시예에 의해 상세히 설명한다 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by way of Examples. However, the following Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples.
재료 및 방법Materials and Methods
1. 발효 홍삼의 제조1. Preparation of fermented red ginseng
홍삼은 (주)오케이바이오랩에서 제공받았으며, 발효 균주는 곰팡이의 일종인 캔디다 유틸리스(Candida utilis) KFRI 566 균주를 한국식품연구원으로부터 분양받아 사용하였고, YM 액체 배지(Yeast Malt broth, Difco)에서 전배양 시킨 KFRI 566 균주(1.0×104 내지 1.0×106 CFU/mL)를 홍삼 분말에 1:1의 비율로 접종한 후 30℃에서 120rpm으로 3일간 액상 발효시키고 60℃에서 8시간 동안 열풍 건조시켜 분말화하였다. Red ginseng was provided by OK Bio Lab, and the fermented strain was Candida utilis KFRI 566 strain, a kind of fungus, purchased from the Korea Food Research Institute and used in YM liquid medium (Yeast Malt broth, Difco). Pre-cultured KFRI 566 strain (1.0×10 4 to 1.0×10 6 CFU/mL) was inoculated with red ginseng powder at a ratio of 1:1, then liquid fermented at 30°C at 120rpm for 3 days, and dried with hot air at 60°C for 8 hours to powder.
2. 발효 홍삼의 추출 조건2. Extraction conditions of fermented red ginseng
추출물은 발효 처리되지 않은 홍삼 분말 및 발효된 홍삼의 건조 분말 100g에 각각 10배의 물을 첨가한 후 37℃에서 3시간씩 3회 환류 추출하였으며 각 추출물을 모아 Adventec 110 mm No.2 여과지(Toyo 2A; Toyo Roshi, 일본)로 여과하여 하기 실시예에 사용하였다. 상기 비발효 홍삼 물 추출물(이하 'NF'라 함)과 발효 홍삼 물 추출물(이하 'F/3 또는 F/3-W'라 함)을 실험에 사용하였으며, 리폭시게나아제 저해 활성의 비교대조군으로 발효된 홍삼의 건조 분말 100g에 70%(v/v) 에탄올을 첨가한 후 상기 동일한 방법으로 발효 홍삼 에탄올 추출물(이하 'F/3-E'라 함)을 제조하여 실험에 사용하였다. Extracts were extracted three times under reflux at 37°C for 3 hours each after adding 10 times water to 100 g of unfermented red ginseng powder and 100 g of dry powder of fermented red ginseng. 2A; Toyo Roshi, Japan) was filtered and used in the following examples. The unfermented red ginseng water extract (hereinafter referred to as 'NF') and fermented red ginseng water extract (hereinafter referred to as 'F/3 or F/3-W') were used in the experiment, and as a comparative control group for lipoxygenase inhibitory activity After adding 70% (v/v) ethanol to 100 g of dry powder of fermented red ginseng, an ethanol extract of fermented red ginseng (hereinafter referred to as 'F/3-E') was prepared and used in the experiment in the same manner.
3. 총 페놀 및 플라보노이드 함량 측정3. Determination of total phenol and flavonoid content
총 페놀 함량은 폴린-데니스(Folin-Denis) 방법을 이용하여 측정하였다. 1%(w/v)의 발효 홍삼 물 추출물 또는 비발효 홍삼 물 추출물에 페놀용액(Folin-ciocalteu's phenol reagent)을 처리하면 페놀성 물질이 인몰리브덴산(phosphomolybdic acid)과 반응하여 청색으로 변하게 되며, 이를 760nm에서 흡광도를 측정하여 측정하였다. 이때 표준 검량 곡선은 탄닌산(tannic acid)을 일정 농도(0~500μg/㎖)로 하여 상기와 동일한 방법으로 측정하여 획득하였으며, 시료의 흡광도를 표준 검량 곡선에 대입하여 총 페놀 함량을 mg/100g로 나타내었다.Total phenol content was determined using the Folin-Denis method. When 1% (w/v) of fermented red ginseng water extract or unfermented red ginseng water extract is treated with a phenol solution (Folin-ciocalteu's phenol reagent), the phenolic substance reacts with phosphomolybdic acid and turns blue. This was measured by measuring the absorbance at 760 nm. At this time, the standard calibration curve was obtained by measuring tannic acid at a certain concentration (0 to 500 μg/ml) in the same manner as above, and substituting the absorbance of the sample into the standard calibration curve to set the total phenol content to mg/100 g. indicated.
총 플라보노이드(flavonoid) 함량을 측정하기 위해, 0.5%(w/v)의 발효 홍삼 물 추출물 또는 비발효 홍삼 물 추출물 0.25㎖에 정제수 1.25㎖과 5% 아질산나트륨(NaNO2) 용액 5㎖을 가하고, 5분 후 10% 염화알루미늄·6수화물(AlCl3·6H2O) 0.15㎖을 혼합하고, 상기 혼합물을 분광광도계를 이용하여 510nm에서 흡광도를 측정하였다. 이때 총 플라보노이드 함량은 표준 물질로서 (+)-카테킨 하이드레이트(catechin hydrate)를 일정 농도(20~200㎍/㎖)로 하여 상기와 동일한 방법으로 측정하여 획득하였으며, 시료의 흡광도를 표준 검량 곡선에 대입하여 총 플라보노이드 함량을 mg/100g로 나타내었다.To measure the total flavonoid content, 1.25 ml of purified water and 5% of a 5% sodium nitrite (NaNO 2 ) solution were added to 0.25 ml of 0.5% (w/v) fermented red ginseng water extract or unfermented red ginseng water extract, After 5 minutes, 0.15 ml of 10% aluminum chloride·hexahydrate (AlCl 3 ·6H 2 O) was mixed, and absorbance of the mixture was measured at 510 nm using a spectrophotometer. At this time, the total flavonoid content was obtained by measuring (+)-catechin hydrate as a standard material in the same manner as above with a certain concentration (20-200 μg/ml), and substituting the absorbance of the sample into the standard calibration curve. Thus, the total flavonoid content was expressed as mg/100g.
4. DPPH 라디칼 소거 활성 측정4. Measurement of DPPH radical scavenging activity
에탄올 100㎖에 DPPH(α,α'-diphenyl-β-picrylhydrazyl) 16㎎을 녹이고 증류수 100㎖을 혼합한 후 Whatman 필터지 NO.2에 여과시켜 DPPH 반응 용액을 제조하였다. 1%(w/v)의 비발효 홍삼 물 추출물 또는 발효 홍삼 물 추출물 1㎖를 취한 후 DPPH 반응 용액 5㎖을 넣어 혼합하고 암소에서 30분간 반응시킨 다음 분광광도계를 이용하여 528nm에서 흡광도를 측정하였다. 이때 활성 비교를 위하여 기존에 항산화제로 많이 사용되고 있는 합성 항산화제 BHT(butylated hydroxytoluene)를 0.05% 농도로 사용하여 시료와 동일한 방법으로 흡광도를 측정하였다. DPPH를 이용한 항산화 활성은 시료 첨가구와 무첨가구의 흡광도차를 백분율(%)로 표시하였다. DPPH 라디칼 소거능 활성(radical scavenging activity)을 구하는 식은 하기와 같다.16 mg of DPPH (α,α'-diphenyl-β-picrylhydrazyl) was dissolved in 100 ml of ethanol, mixed with 100 ml of distilled water, and filtered through Whatman filter paper NO.2 to prepare a DPPH reaction solution. After taking 1 ml of 1% (w/v) unfermented red ginseng water extract or fermented red ginseng water extract, 5 ml of DPPH reaction solution was added, mixed, and reacted in a dark place for 30 minutes, and then absorbance was measured at 528 nm using a spectrophotometer. . At this time, for activity comparison, the absorbance was measured in the same manner as in the sample by using the synthetic antioxidant BHT (butylated hydroxytoluene), which has been widely used as an antioxidant, at a concentration of 0.05%. Antioxidant activity using DPPH was expressed as a percentage (%) difference in absorbance between the sample-added group and the non-additive group. The formula for calculating the DPPH radical scavenging activity is as follows.
DPPH 라디칼 소거능 활성(%)=[1-(시료 흡광도528nm)/대조구 흡광도528nm]×100DPPH radical scavenging activity (%) = [1- (sample absorbance 528 nm ) / control absorbance 528 nm ] × 100
5. 리폭시게나아제(lipoxygenase) 억제 활성5. Lipoxygenase Inhibitory Activity
1%(w/v)의 비발효 홍삼 물 추출물 또는 발효 홍삼 물 추출물 100㎕와 200mM 보레이트 완충액(borate buffer, pH 9.0) 1㎖을 넣은 후 기질인 리놀렌산(linoleic acid, 0.6 mM/㎖ in ethanol) 2㎖을 넣고 혼합한 후 234nm에서 보정값을 측정한 다음, 리폭시게나아제 10,000 unit/㎖ 100㎕를 넣고 상온에서 10분간 반응시킨 후 234nm에서 흡광도를 측정하였으며, 양성대조군은 인도메타신(indomethacin, Sigma)을 0.05%(w/v)로 에탄올에 녹여서 사용하였다.After adding 100 μl of 1% (w/v) water extract of unfermented red ginseng or water extract of fermented red ginseng and 1 ml of 200 mM borate buffer (borate buffer, pH 9.0), the substrate linoleic acid (0.6 mM/ml in ethanol) After adding 2 ml and mixing, the correction value was measured at 234 nm, and 100 μl of lipoxygenase 10,000 unit/ml was added, reacted at room temperature for 10 minutes, and absorbance was measured at 234 nm. Sigma) was dissolved in ethanol at 0.05% (w/v) and used.
리폭시게나아제 억제활성(%)={1-(b'-b)/(a'-a)}×100Lipoxygenase inhibitory activity (%) = {1-(b'-b)/(a'-a)}×100
b: 효소 무첨가 시료’b: Enzyme-free sample’
b : 효소 첨가 시료군b: enzyme-added sample group
a: 효소 무첨가 blank 군a: enzyme-free blank group
a': 효소 첨가 blank 군a': enzyme-added blank group
6. 통계처리6. Statistical processing
상기 실험으로부터 얻어진 결과는 one-way ANOVA 검정에 의한 평균±표준편차로 표시하였고, 각 실험 군 간의 유의성 검증은 Duncan's multiple range test로 나타내었다.The results obtained from the above experiments were expressed as mean ± standard deviation by one-way ANOVA test, and the significance test between each experimental group was indicated by Duncan's multiple range test.
실시예Example 1. 발효 홍삼 물 추출물의 총 페놀 및 플라보노이드 함량 분석 1. Analysis of Total Phenol and Flavonoid Content of Fermented Red Ginseng Water Extract
비발효 홍삼 물 추출물과 발효 홍삼 물 추출물의 총 페놀 함량을 측정한 결과, 도 1에 개시한 바와 같이 총 페놀 함량은 NF군에서 약 10mg/100g인 반면, F/3군에서 약 12mg/100g인 것으로, 비발효 홍삼 물 추출물에 비해 발효 홍삼 물 추출물에서 총 페놀 함량이 미량 증가하였고, 총 플라보노이드 함량을 측정한 결과, 비발효 홍삼 물 추출물에서는 총 플라보노이드가 정량화되지 않는 반면, 발효 홍삼 물 추출물에서는 약 0.45mg/100g의 총 플라보노이드 함량이 측정되어, 발효 공정에 의해 플라보노이드의 함량이 현저히 증가됨을 알 수 있었다(도 2).As a result of measuring the total phenol content of the unfermented red ginseng water extract and the fermented red ginseng water extract, the total phenol content was about 10 mg/100 g in the NF group, while the total phenol content was about 12 mg/100 g in the F/3 group. As a result, the total phenol content was slightly increased in the water extract of fermented red ginseng compared to the water extract of unfermented red ginseng. The total flavonoid content of 0.45 mg/100 g was measured, and it was found that the content of flavonoids was significantly increased by the fermentation process (FIG. 2).
실시예Example 2. 발효 홍삼 물 추출물의 2. Fermented Red Ginseng Water Extract DPPHDPPH 라디칼radical 소거 활성 분석 Scavenging Activity Assay
비발효 홍삼 물 추출물 및 발효 홍삼 물 추출물의 DPPH 라디칼 소거 활성을 측정하였고, 양성대조군에는 시중에서 판매하고 있는 합성 항산화제인 BHT(butylated hydroxytoluene) 0.05%를 처리하였다. 그 결과, DPPH 라디칼 소거 활성이 비발효 홍삼 물 추출물 처리군(NF)에서 30%인 반면, 발효 홍삼 물 추출물 처리군(F/3)에서 40%로 NF군 및 F/3군 간에 통계적으로 유의한 차이가 있는 것을 확인하였다(도 3).The DPPH radical scavenging activity of unfermented red ginseng water extract and fermented red ginseng water extract was measured, and the positive control group was treated with 0.05% of commercially available synthetic antioxidant BHT (butylated hydroxytoluene). As a result, while the DPPH radical scavenging activity was 30% in the non-fermented red ginseng water extract treatment group (NF), it was 40% in the fermented red ginseng water extract treatment group (F/3), which was statistically significant between the NF and F/3 groups. It was confirmed that there was one difference (FIG. 3).
실시예 3. 발효 홍삼 물 추출물의 리폭시게나아제 저해 활성 분석Example 3. Lipoxygenase inhibitory activity analysis of fermented red ginseng water extract
리폭시게나아제(lipoxygenase)는 정상적인 세포에서는 발현이 미비하지만, 염증이 유발되면 류코트리엔(leukotrienes) 물질의 증가로 인해 활성을 나타낸다. 리폭시게나아제 효소의 저해 활성 측정에 있어서, 양성대조군에는 시중에서 판매하고 있는 인도메타신(indomethacin) 0.05%를 처리하였다.Lipoxygenase (lipoxygenase) is poorly expressed in normal cells, but exhibits activity due to an increase in leukotrienes when inflammation is induced. In the measurement of the inhibitory activity of the lipoxygenase enzyme, the positive control group was treated with commercially available indomethacin 0.05%.
비발효 홍삼 물 추출물(NF)과 추출 용매에 따라 제조된 발효 홍삼 물 추출물(F/3-W) 및 발효 홍삼 에탄올 추출물(F/3-E)의 리폭시게나아제 저해 활성을 측정하여 비교한 결과, 리폭시게나아제 저해 활성이 비발효 홍삼 물 추출물 처리군(NF)에서 약 12%인 반면에, 발효 홍삼 추출물 처리군에서 리폭시게나아제 저해 활성이 증가되었으며, 특히 발효 홍삼 물 추출물 처리군(F/3-W)의 경우 NF군에 비해 리폭시게나아제 저해 활성이 약 3배 증가되었으며, 발효 홍삼 물 추출물 처리군(F/3-W) 및 발효 홍삼 에탄올 추출물 처리군(F/3-E) 간에 통계적으로 유의한 차이가 있는 것을 확인하였다(도 4).The result of measuring and comparing the lipoxygenase inhibitory activity of non-fermented red ginseng water extract (NF), fermented red ginseng water extract (F/3-W) and fermented red ginseng ethanol extract (F/3-E) prepared according to the extraction solvent , While the lipoxygenase inhibitory activity was about 12% in the non-fermented red ginseng water extract treatment group (NF), the lipoxygenase inhibitory activity was increased in the fermented red ginseng extract treatment group, especially in the fermented red ginseng water extract treatment group (F/ 3-W), the lipoxygenase inhibitory activity was increased about 3 times compared to the NF group, and between the fermented red ginseng water extract treatment group (F/3-W) and the fermented red ginseng ethanol extract treatment group (F/3-E) It was confirmed that there was a statistically significant difference (FIG. 4).
실시예 4. 발효 균주 및 기간에 따른 리폭시게나아제 저해 활성 분석Example 4. Lipoxygenase inhibitory activity analysis according to fermentation strain and period
상기 '발효 홍삼의 제조'와 동일한 방법으로 발효 균주(Lactobacillus casei ATCC 393, Bacillus subtilis KACC 91157 및 Candida utilis KFRI 566)별로 발효 1일 기준으로 발효 홍삼 물 추출물을 각각 제조하여 리폭시게나아제 저해 활성을 측정하였다. 그 결과, NF 처리군과 비교하여 락토바실러스 카제이(Lactobacillus casei, Lc)를 접종하여 제조한 발효 홍삼 물 추출물의 경우에 리폭시게나아제 저해 활성 변화가 없었지만, 바실러스 서틸리스(Bacillus subtilis, Bs) 및 캔디다 유틸리스(Candida utilis, Cu)를 접종하여 제조한 발효 홍삼 물 추출물의 경우에는 리폭시게나아제 저해 활성이 증가되었으며, 특히 발효 균주로 캔디다 유틸리스를 접종한 경우 바실러스 서틸리스에 비해 리폭시게나아제 저해 활성이 통계적으로 유의하게 증가한 것을 확인하였다(도 5). Fermented strains (Lactobacillus casei ATCC 393, Bacillus subtilis KACC 91157) in the same manner as in the 'production of fermented red ginseng' and Candida utilis KFRI 566), respectively, fermented red ginseng water extracts were prepared on the basis of the first day of fermentation, and lipoxygenase inhibitory activity was measured. As a result, compared to the NF treatment group, Lactobacillus casei ( Lactobacillus casei , In the case of the fermented red ginseng water extract prepared by inoculating Lc), there was no change in lipoxygenase inhibitory activity, but Bacillus subtilis ( Bacillus subtilis , Bs) and Candida utilis , In the case of the fermented red ginseng water extract prepared by inoculating Cu), the lipoxygenase inhibitory activity was increased. It was confirmed that there was an increase (FIG. 5).
또한, 캔디다 유틸리스(Cu) 균주를 접종하여 발효 기간(1, 2, 3, 4 및 5일)별로 발효 홍삼 물 추출물을 제조하여 리폭시게나아제 저해 활성을 측정한 결과, 발효 기간 중 3일째에서 리폭시게나아제 저해 활성이 가장 우수한 것을 확인하였다(도 6).In addition, by inoculating Candida utilis (Cu) strain and preparing fermented red ginseng water extract for each fermentation period (1, 2, 3, 4 and 5 days), the lipoxygenase inhibitory activity was measured. It was confirmed that the lipoxygenase inhibitory activity was the most excellent (FIG. 6).
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190175949A KR102350102B1 (en) | 2019-12-27 | 2019-12-27 | Composition for anti-inflammation comprising extract of fermented red ginseng with improved antioxidant activity as effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190175949A KR102350102B1 (en) | 2019-12-27 | 2019-12-27 | Composition for anti-inflammation comprising extract of fermented red ginseng with improved antioxidant activity as effective component |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210083557A KR20210083557A (en) | 2021-07-07 |
| KR102350102B1 true KR102350102B1 (en) | 2022-01-12 |
Family
ID=76862615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190175949A KR102350102B1 (en) | 2019-12-27 | 2019-12-27 | Composition for anti-inflammation comprising extract of fermented red ginseng with improved antioxidant activity as effective component |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102350102B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102519489B1 (en) | 2022-07-04 | 2023-04-11 | (주)제이비 바이오 | A composition for improving prostate or sexual function comprising a high content of compound K, which has increased absorption into the body through solid fermentation |
| KR102549447B1 (en) | 2022-06-10 | 2023-07-03 | (주)제이비 바이오 | Compound comprising a high content of compound K, which has increased absorption into the body through solid-phase fermentation and anti-cancer, antioxidant, anti-inflammatory or immune-enhancing composition containing it |
-
2019
- 2019-12-27 KR KR1020190175949A patent/KR102350102B1/en active IP Right Grant
Non-Patent Citations (3)
| Title |
|---|
| 김영호 외 1인. 증폭시킨 홍삼으로부터 분리한 ginsenoside Rh2, compound K의 융복합적 항암 및 항염효과. Journal of Digital Convergence, Nov 2017, Vol. 15, No. 11, pp. 285-295 1부.* |
| 박혜진 외 6인. 홍삼과 발효홍삼의 항염증 작용 및 항알러지 효과 비교. Korean J. Plant Res. 2010, Vol. 23, No. 5, pp. 415~422 1부. |
| 황성인 외 8인. 발효 홍삼의 NF-B 신호전달 조절을 통한 항염증 효과. Journal of Physiology & Pathology in Korean Medicine. 2011.6, Vol. 25, No. 3, pp. 521-527 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102549447B1 (en) | 2022-06-10 | 2023-07-03 | (주)제이비 바이오 | Compound comprising a high content of compound K, which has increased absorption into the body through solid-phase fermentation and anti-cancer, antioxidant, anti-inflammatory or immune-enhancing composition containing it |
| KR102519489B1 (en) | 2022-07-04 | 2023-04-11 | (주)제이비 바이오 | A composition for improving prostate or sexual function comprising a high content of compound K, which has increased absorption into the body through solid fermentation |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210083557A (en) | 2021-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102314654B1 (en) | Composition for skin wrinkle improvement or anti-inflammation comprising extract of fermented Centella asiatica with improved antioxidant activity as effective component | |
| KR102048309B1 (en) | Composition for preventing, improving or treating thrombosis comprising extract of fermented Tenebrio molitor as effective component | |
| CN115087728B (en) | Novel lactobacillus sakei HEM224 strain and composition for treating inflammation or asthma comprising said strain or culture thereof | |
| KR102350102B1 (en) | Composition for anti-inflammation comprising extract of fermented red ginseng with improved antioxidant activity as effective component | |
| KR20090025469A (en) | Pharmaceutical composition for the prevention and treatment of inflammatory diseases or the alleviation of pain containing extract of gastrodia elata | |
| KR102083275B1 (en) | Composition for preventing, improving or treating thrombosis comprising extract of fermented Protaetia brevitarsis seulensis larvae as effective component | |
| KR101756020B1 (en) | Composition for Prevention, Improvement, or Treatment of Atopic Dermatitis Comprising Fermented Extract of Alnus sibirica Fitch. ex Turcz. | |
| KR102314639B1 (en) | Composition for anti-inflammation comprising extract of fermented bamboo shoot bark with improved antioxidant activity as effective component | |
| KR102159607B1 (en) | Composition for skin whitening or anti-inflammatory comprising extract of fermented Angelica gigas with improved antioxidant activity as effective component | |
| KR20170106187A (en) | Antioxidant Composition | |
| KR101494664B1 (en) | fermented corni fructus composition with antioxidant activity and method of making the same | |
| KR102368892B1 (en) | A composition for anti-inflammatory comprising extracts of single leaf cremastra and sigesbeckia glabrescens makino | |
| KR20200023576A (en) | Composition for improving hepatic function comprising extract of fermented Protaetia brevitarsis larva as effective component | |
| KR101302652B1 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES MELLITUS COMPRISING α-GLUCOSIDASE INHIBITOR AND BREWER'S DRIED YEAST | |
| KR20190136769A (en) | Composition for antioxidant and anti-inflammatory comprising fraction of Ledum palustre L. extract as effective component | |
| KR20160079269A (en) | Anti-inflammatory pharmaceutical composition and health functional food containing artemisia fermentation extract | |
| KR102048434B1 (en) | A composition as a prebiotic for improving intestinal microflora containing High-molecular fraction from radish leave | |
| KR102042151B1 (en) | A composition as a prebiotic for improving intestinal microflora containing extract from pepper leaves | |
| KR101482044B1 (en) | Food composition comprising fermented product of Pleuropterus multiflorus and ginger for alleviating or preventing degenerative brain disorder and method of producing the same | |
| KR101695507B1 (en) | Composition comprising fermented Oenanthe Javanica organic acid extract for anti-inflammation | |
| KR20130087174A (en) | Pharmaceutical composition comprising water extract of broccoli for preventing or treating inflammatory disease | |
| KR20230139906A (en) | Composition containing as active ingredients red ginseng and hazelnut extract with improved lung function improvement effect | |
| KR102098914B1 (en) | Composition of anti-inflammatory or anti-oxidation containing natto and kefir fermented component | |
| KR102483814B1 (en) | Compositions for Anti-Bacterial and Anti-Inflammatory Effect Comprising Oil of Ulvoid green algae | |
| KR101624293B1 (en) | Composition for enhancing immune response comprising extract of Benincasa hispida Cogniaux or fermented extract of the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |